Quoted: Dr. Cynthia Carlsson, Professor of Medicine at the University of Wisconsin-Madison, said Leqembi targets deposits of proteins in the brain called amyloid. Amyloid is believed to contribute to the symptoms of Alzheimer’s Disease.
“What was impressive about this study is that it improved the amyloid levels in the brain, lowered those. It improved their cognition, improved their function, improved their quality of life, all of these things we really care about, as well as, what the brain looks like,” Carlsson said.
Carlsson told CBS 58 the drug is primarily given to people with mild Alzheimer’s symptoms intravenously every two weeks.
She said side effects can include increased risk of micro bleeds and swelling in the brain.
“The results from the clarity study showed pretty vigorous responses across all of these outcome measures, which we hadn’t seen for a therapy like this before,” Carlsson said.